Aldeyra Therapeutics (ALDX) Capital Expenditures (2014 - 2022)
Aldeyra Therapeutics' (ALDX) quarterly Capital Expenditures came in at $16317.0 in Q1 2022, up 109.03% YoY from $7806.0 in Q1 2021, and up 109.03% on a QoQ basis from $7806.0 in Q1 2021.
Aldeyra Therapeutics (ALDX) Capital Expenditures (2014 - 2022) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 8 years of Capital Expenditures data on file, last reported at $16317.0 in Q1 2022.
- Quarterly Capital Expenditures rose 109.03% year-over-year to $16317.0 in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $16317.0 (up 109.03% YoY) and the FY2022 annual result came in at $16317.0, up 109.03% from the prior year.
- Capital Expenditures grew to $16317.0 in Q1 2022, from $7806.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $139006.0 in Q1 2018 to a low of $4604.0 in Q2 2019.
- A 4-year average of $37077.2 and a median of $15450.5 in 2018 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2018 — Capital Expenditures soared 1099.15% — and 2019, when it tumbled 96.46%.
- Tracing ALDX's Capital Expenditures over 4 years: stood at $14584.0 in 2018, then sank by 68.43% to $4604.0 in 2019, then jumped by 69.55% to $7806.0 in 2021, then surged by 109.03% to $16317.0 in 2022.
- The last three Capital Expenditures figures came in at $16317.0 (Q1 2022), $7806.0 (Q1 2021), and $4604.0 (Q2 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 16,317.00 |
| Mar 31, 2022 | 16,317.00 |
| Mar 31, 2021 | 7,806.00 |
| Mar 31, 2021 | 7,806.00 |
| Jun 30, 2019 | 4,604.00 |
| Jun 30, 2019 | 4,604.00 |
| Mar 31, 2019 | 4,925.00 |
| Mar 31, 2019 | 4,925.00 |
| Dec 31, 2018 | 14,584.00 |
| Dec 31, 2018 | 14,584.00 |
| Sep 30, 2018 | 47,619.00 |
| Sep 30, 2018 | 47,619.00 |
| Jun 30, 2018 | 61,757.00 |
| Jun 30, 2018 | 61,757.00 |
| Mar 31, 2018 | 139,006.00 |
| Mar 31, 2018 | 139,006.00 |
| Dec 31, 2017 | 13,167.00 |
| Dec 31, 2017 | 13,167.00 |
| Mar 31, 2017 | 11,592.00 |
| Mar 31, 2017 | 11,592.00 |